FY2017 EPS Estimates for Vanda Pharmaceuticals Inc. Increased by Jefferies Group (VNDA)

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Investment analysts at Jefferies Group upped their FY2017 earnings per share (EPS) estimates for shares of Vanda Pharmaceuticals in a note issued to investors on Wednesday. Jefferies Group analyst M. Andrews now expects that the biopharmaceutical company will earn ($0.43) per share for the year, up from their prior estimate of ($0.53). Jefferies Group currently has a “Buy” rating and a $21.00 target price on the stock. Jefferies Group also issued estimates for Vanda Pharmaceuticals’ Q4 2017 earnings at ($0.13) EPS.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.10). The firm had revenue of $41.30 million for the quarter, compared to analysts’ expectations of $43.90 million. Vanda Pharmaceuticals had a negative net margin of 9.01% and a negative return on equity of 10.99%. The firm’s revenue was up 7.3% compared to the same quarter last year. During the same quarter last year, the company earned ($0.01) earnings per share.

COPYRIGHT VIOLATION NOTICE: “FY2017 EPS Estimates for Vanda Pharmaceuticals Inc. Increased by Jefferies Group (VNDA)” was originally reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The correct version of this piece of content can be viewed at https://www.chaffeybreeze.com/2017/11/15/fy2017-eps-estimates-for-vanda-pharmaceuticals-inc-increased-by-jefferies-group-vnda.html.

Several other equities analysts have also commented on the stock. Zacks Investment Research lowered shares of Vanda Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, October 26th. Piper Jaffray Companies increased their price target on shares of Vanda Pharmaceuticals from $23.00 to $26.00 and gave the company an “overweight” rating in a research note on Thursday, September 14th. Oppenheimer Holdings, Inc. set a $26.00 price target on shares of Vanda Pharmaceuticals and gave the company a “buy” rating in a research note on Sunday, October 29th. Finally, BidaskClub upgraded shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, August 22nd. One analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $21.50.

Shares of Vanda Pharmaceuticals (VNDA) opened at $12.95 on Monday. Vanda Pharmaceuticals has a 1-year low of $11.90 and a 1-year high of $18.99.

A number of institutional investors have recently made changes to their positions in VNDA. Legal & General Group Plc increased its stake in Vanda Pharmaceuticals by 37.4% in the second quarter. Legal & General Group Plc now owns 11,105 shares of the biopharmaceutical company’s stock valued at $181,000 after purchasing an additional 3,022 shares during the last quarter. Kopp Investment Advisors LLC purchased a new position in shares of Vanda Pharmaceuticals during the second quarter worth approximately $196,000. Los Angeles Capital Management & Equity Research Inc. purchased a new position in shares of Vanda Pharmaceuticals during the third quarter worth approximately $277,000. American International Group Inc. grew its position in shares of Vanda Pharmaceuticals by 7.1% during the first quarter. American International Group Inc. now owns 22,563 shares of the biopharmaceutical company’s stock worth $316,000 after acquiring an additional 1,491 shares during the last quarter. Finally, Voya Investment Management LLC grew its position in shares of Vanda Pharmaceuticals by 29.7% during the second quarter. Voya Investment Management LLC now owns 20,118 shares of the biopharmaceutical company’s stock worth $328,000 after acquiring an additional 4,605 shares during the last quarter. Institutional investors own 87.28% of the company’s stock.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Earnings History and Estimates for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply